Naxitamab is approved in the United States (US), Israel, China, Brazil, and Mexico, among other countries, in combination with GM-CSF, for the treatment of pediatric (1 year of age and older) and adult patients with relapsed or refractory (R/R) HR neuroblastoma in the bone/BM who have demonstrated a partial response (PR), minor response (MR), or stable disease (SD) to prior therapy35. The gene discussed is CSF2; the disease is neuroblastoma.